TIGIT and melanoma: The translational potential of dual PD-1/TIGIT inhibition has already been demonstrated; it increases the proliferation and function of intratumoral antigen-specific CD8+ T cells in melanoma patients to an extent that is much more dramatic than a single blockade (119, 125).